Peritoneal (Abdominal Mesothelioma)
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
BMC Cancer 2021 March 20 [Link] Rui Kitadai, Tatsunori Shimoi, Kazuki Sudo, Emi Noguchi, Yusuke Nagata, Ryoichi Sawada, Atsuo Takashima, Narikazu Boku, Kan Yonemori Abstract Background: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed…
Read MoreOutcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
BJS Open 2021 March 5 [Link] A Zahid, L Clarke, N Carr, K Chandrakumaran, A Tzivanakis, S Dayal, F Mohamed, T Cecil, B J Moran Abstract Background: Multicystic peritoneal mesothelioma (MCPM) is a rare neoplasm, generally considered a borderline malignancy, best treated by cytoreductive surgery (CRS) to remove macroscopic disease, combined with hyperthermic intraperitoneal chemotherapy…
Read MoreTRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared to malignant mesothelioma
Human Pathology 2021 March 2 [Link] Hiroe Itami, Tomomi Fujii, Tokiko Nakai, Maiko Takeda, Yohei Kishi, Fumiaki Taniguchi, Chiyoko Terada 2, Fumi Okada, Yuji Nitta, Minami Matsuoka, Shoh Sasaki, Sumire Sugimoto, Tomoko Uchiyama, Kohei Morita, Takahiko Kasai, Ryuji Kawaguchi, Chiho Ohbayashi Abstract Adenomatoid tumors (ATs) are benign mesothelial tumors with good prognosis and usually occur…
Read MoreTRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared to malignant mesothelioma
Human Pathology 2021 March 2 [Link] Hiroe Itami, Tomomi Fujii, Tokiko Nakai, Maiko Takeda, Yohei Kishi, Fumiaki Taniguchi, Chiyoko Terada, Fumi Okada, Yuji Nitta, Minami Matsuoka, Shoh Sasaki, Sumire Sugimoto, Tomoko Uchiyama, Kohei Morita, Takahiko Kasai, Ryuji Kawaguchi, Chiho Ohbayashi Abstract Adenomatoid tumors (ATs) are benign mesothelial tumors with good prognosis and usually occur in…
Read MorePhase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
Investigational New Drugs 2021 March 4 [Link] Marjorie G Zauderer, Evan W Alley, Johanna Bendell, Enrica Capelletto, Todd M Bauer, Sophie Callies, Anna M Szpurka, Suhyun Kang, Melinda D Willard, Volker Wacheck, Anna M Varghese Abstract BACKGROUND LY3023414 is a selective, ATP competitive inhibitor of class I PI3K isoforms, mTORC1/2 and DNA-PK. A Phase 1…
Read MoreA novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20 : a case report and literature review
The Oncologist 2021 February 8 [Link] Chiho Miyagawa, Hisamitsu Takaya, Kazuko Sakai, Kazuto Nishio, Maho Konishi, Sachiko Minamiguchi, Toshihide Shimada, Noriomi Matsumura Abstract Recently, several malignant peritoneal mesothelioma (MPMs) that occur in young women without asbestos exposure and with fusion genes such as anaplastic lymphoma kinase (ALK) and Ewing sarcoma breakpoint region 1 (EWSR1) have…
Read MoreSTRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells
Translational Oncology 2021 January 30 [Link] Astrid Murumägi, Daniela Ungureanu, Mariliina Arjama, Ralf Bützow, Jouko Lohi, Hannu Sariola, Jukka Kanerva, Minna Koskenvuo, Olli Kallioniemi Abstract Genetic rearrangements involving the anaplastic lymphoma kinase (ALK) gene create oncogenic drivers for several cancers, including malignant peritoneal mesothelioma (MPeM). Here, we report genomic and functional precision oncology profiling on…
Read MoreRucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
The Lancet Respiratory Medicine 2021 January 27 [Link] Dean A Fennell, Amy King, Seid Mohammed, Amy Branson, Cassandra Brookes, Liz Darlison, Alan G Dawson, Aarti Gaba, Margaret Hutka, Bruno Morgan, Adrian Nicholson, Cathy Richards, Peter Wells-Jordan, Gavin James Murphy, Anne Thomas Abstract Background: Malignant mesothelioma remains an incurable cancer, with no effective treatments in the…
Read MoreUnusual radiologic presentations of malignant peritoneal mesothelioma
World Journal of Radiology 2020 December 28 [Link] Paul Hendrick Sugarbaker, James S Jelinek Abstract Background: Malignant peritoneal mesothelioma is an unusual disease process characterized radiologically by ascites and infiltration of the peritoneum by multiple small tumor nodules. Both parietal and visceral peritoneum are involved by the multiple malignant tumor nodules. Computed tomography (CT) has…
Read MoreEstablishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma
Experimental Animals 2021 January 21 [Link] Zhi-Ran Yang, Zhi-Gao Chen, Zhong-He Ji, Yu-Lin Lin, Jue Zhang, Ru Ma, Zhao Li, Xi Jiang, Qian Chen, Xue-Mei DU, Yan Li Abstract Malignant peritoneal mesothelioma (MPM) is a rare malignancy with few experimental models. This study used the human surgical specimen to establish MPM patient-derived xenograft (PDX) models…
Read More